Inhibition of CTGF Over-expression in Diabetic Retinopathy by SERPINA3K via Blocking the WNT/Beta-catenin Pathway

**Running Title:** A Novel Anti-fibrogenic Factor

Bin Zhang, Kevin K. Zhou and Jian-xing Ma*

Department of Cell Biology, Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104

*Corresponding Author:
Jian-xing Ma, M.D., Ph.D.
E-mail: jian-xing-ma@ouhsc.edu

Submitted 17 July 2009 and accepted 6 March 2010.

Additional information for this article can be found in an online appendix at [http://diabetes.diabetesjournals.org](http://diabetes.diabetesjournals.org)

This is an uncopyedited electronic version of an article accepted for publication in *Diabetes*. The American Diabetes Association, publisher of *Diabetes*, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of *Diabetes* in print and online at [http://diabetes.diabetesjournals.org](http://diabetes.diabetesjournals.org).
Objective: Connective tissue growth factor (CTGF) is a major fibrogenic factor. Increased retinal CTGF levels have been implicated to play a role in diabetic retinopathy (DR). SERPINA3K is a serine proteinase inhibitor, and its levels were decreased in the retinas with DR. The purpose of this study was to investigate the role of SERPINA3K in the regulation of CTGF and fibrogenesis, and its mechanism of action.

Research Design and Methods: Adenovirus expressing SERPINA3K was injected intravitreally into streptozotocin-induced diabetic rats. CTGF expression was measured using Western blot analysis and real-time RT-PCR. Fibrosis was evaluated by quantifying retinal fibronectin using ELISA. Wnt pathway activation was determined by phosphorylation of low-density lipoprotein receptor-related protein 6 (LRP6), a co-receptor of Wnt ligands, and stabilization of beta-catenin, an essential effector of the canonical Wnt pathway.

Results: Ad-SERPINA3K attenuated the CTGF and fibronectin over-expression in the retinas of diabetic rats. In cultured retinal cells, SERPINA3K blocked the over-production of CTGF induced by high glucose. DKK1, a specific Wnt antagonist, also attenuated the high glucose-induced CTGF over-expression, indicating a role of Wnt signaling in CTGF over-expression in diabetes. Similarly, increased SERPINA3K blocked Wnt pathway activation in the diabetic retinas and in cells treated with high glucose. Further, SERPINA3K also attenuated the Wnt3a-induced activation of the canonical Wnt pathway and the over-expression of CTGF.

Conclusion: SERPINA3K is an anti-fibrogenic factor and its anti-fibrogenic activity is through blocking the Wnt pathway. Decreased SERPINA3K levels may contribute to the fibrosis in DR.
SERPINA3K, a serine proteinase inhibitor (serpin), is expressed in the liver, kidney, pancreas and retina (1-3). SERPINA3K specifically binds to tissue kallikrein to form a covalent complex and inhibits proteolytic activities of tissue kallikrein (3), and is believed to participate in the regulation of vasodilation and local blood flow via interactions with the kallikrein-kinin system (4). Later studies suggest that SERPINA3K has other functions independent of inhibition of tissue kallikrein. For example, SERPINA3K has been found to inhibit retinal neovascularization (NV) in the ischemia-induced retinopathy, which is not dependent on its interactions with the kallikrein-kinin system (5). Further, in a diabetic rat model, SERPINA3K levels have been shown to decrease in the retinas, suggesting that decreased SERPINA3K levels may contribute to diabetic retinopathy (DR) (6).

DR is one of the leading causes of blindness (7). In advanced stages of DR, retinal fibrosis occurs and fibrovascular contraction can cause haemorrhages and retinal detachment (7; 8). Connective tissue growth factor (CTGF) is a pro-fibrogenic factor which stimulates fibroblast proliferation, cell adhesion, and extracellular matrix production (9; 10). The potential role of CTGF in pathological fibrosis has been established (11), and CTGF has been suggested to be an attractive therapeutic target in some fibrotic diseases (12). The protein and mRNA levels of CTGF were found to be elevated in the retinas with DR (13), and the roles of CTGF in fibrovascular proliferation and thickening of capillary basement membrane were also demonstrated in proliferative DR (13-16). All of these previous findings suggest a therapeutic potential for anti-CTGF therapy in DR.

Wnts are a group of secreted, cysteine-rich glycoproteins (17). As shown in Figure S1 (available in the online appendix at http://diabetes.diabetesjournals.org), in the absence of Wnt ligands, transcription factor β-catenin, a down-stream effector of the canonical Wnt pathway, is phosphorylated by a protein complex containing GSK-3 in the cytosol and constantly degraded to prevent its accumulation (18; 19). Upon binding of certain Wnt ligands, the Frizzled (Fz) receptor dimerizes with the co-receptor, low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6), forming a receptor/co-receptor complex (17). As a result, the downstream signaling is stimulated, including phosphorylation of LRP5/6 and stabilization of β-catenin (20; 21). β-catenin is subsequently translocated into the nucleus, associates with T cell factor (TCF) for DNA binding and regulates expression of target genes including CTGF (17).

The Wnt signaling pathway is involved in multiple physiological and pathological processes. It has been well studied in embryogenesis and carcinogenesis (22). Recent evidence suggests that the Wnt pathway is also important in ocular diseases, for example, mutations in the Fz receptor and LRP co-receptor have been shown to associate with the vascular developmental defects (23). Furthermore, it has been revealed that Wnt signaling is responsible for pathological fibrosis in the lung, suggesting that inhibition of Wnt signaling, such as Wnt antagonists, may represent a therapeutic option (24-27). As a pro-fibrogenic factor, CTGF was also found to be regulated by Wnt signaling in osteoblast differentiation (28; 29). However, there is little previous evidence to implicate Wnt signaling in fibrosis in the retina with DR.

In the present study, we have investigated the inhibitory effect of SERPINA3K on the hyperglycemia-induced CTGF over-expression and Wnt pathway activation, and further determined if the
beneficial effects of SERPINA3K in DR are through the Wnt antagonistic activity.

RESEARCH DESIGN AND METHODS

Cell Culture: rMC-1, a cell line derived from rat retinal Müller cells, is a kind gift from Dr. Vijay Sarthy at Northwestern University, and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Cellgro, Manassas, VA) containing 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA) (30). HTERT-RPE, a cell line derived from human RPE cells, was purchased from ATCC (Manassas, VA) and cultured in DMEM containing 10% FBS following the ATCC recommendation. L cells and L cells stably expressing Wnt3A (L-Wnt3a) were purchased from ATCC and cultured in DMEM containing 10% FBS and 0.4 mg/ml G-418 (Invitrogen, Carlsbad, CA). The cells and conditioned media (1 g/L glucose, 1% FBS) were harvested following the procedure recommended by ATCC. The cultured cells were starved in 1 g/L glucose (5 mM) DMEM containing 1% FBS overnight before treatment. For high glucose (HG) treatment, the cells were exposed to 30 mM D-glucose (Sigma, St. Louis, MO), and the low glucose control (LG) included 5 mM D-glucose and 25 mM L-glucose (Sigma, St. Louis, MO) in the culture medium.

Experimental Animals: Brown Norway (BN) rats were purchased from Charles River Laboratories (Wilmington, MA). Care, use, and treatment of all animals in this study were in strict agreement with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the guidelines in the Care and Use of Laboratory Animals set forth by the University of Oklahoma.

Induction of Experimental Diabetes: The experimental diabetes was induced as described previously (31). Briefly, BN rats (8 week of age) were given a single intraperitoneal injection of streptozotocin (STZ, 50 mg/kg in 10 mmol/L of citrate buffer, pH 4.5) after overnight fasting. Serum glucose levels were monitored 48 hr after the STZ injection and every two weeks thereafter, and only the animals with blood glucose levels higher than 350 mg/dl were used as diabetic rats.

Recombinant Proteins, Adenovirus, Plasmids, Transfection and Reporter Assay; The SERPINA3K cDNA was cloned into the pET28 vector (Novagen, Madison, WIS) and the construct was transformed into E. coli strain BL-21/DE3 (Novagen, Madison, WIS). The expression and purification followed the protocol described previously (5). Endotoxin levels were measured using a limulus amebocyte kit (Biowhittaker, Walkersville, MD). Bovine serum albumin (BSA) (Sigma St. Louis, MO) was used as protein control for SERPINA3K. Recombinant Dickkopf-1 (DKK1) protein was purchased from R&D Systems (Minneapolis, MN). To clone the SERPINA3K cDNA, total RNA was extracted from the liver and was reverse transcribed to cDNA. The full-length sequence of SERPINA3K containing the signal peptide was cloned into the shuttle vector. The adenoviral vector used in the study is human adenovirus serotype 5 (Ad5). Adenoviruses expressing SERPINA3K and LacZ were generated using AdEasy systems from Qbiogene (Irvine, CA) following manufacturer’s protocol. These adenoviruses were purified using Adeno-X Virus Purification Kits from BD (San Jose, CA). TOPFLASH vector was constructed as described (32). Fugene 6 (Roche Applied Science, Indianapolis, IN) was used for transfection following manufacturer’s protocol. Luciferase reporter assays were performed in 12-well plates. The TOPFLASH construct and renilla luciferase pRL-TK vector were co-transfected into the cells. TOPFLASH activity was measured using the dual luciferase reporter system (Promega,
A Novel Anti-fibrogenic Factor

Madison, WI) and normalized by renilla luciferase activity.

**Real-time RT-PCR:** Total RNA was isolated using RNeasy Mini Kit (Qiagen Sciences, Germantown, MD). mRNA was reverse transcribed to cDNA using TaqMan kit from Roche (Indianapolis, IN). This cDNA was then used for specific real-time PCR. The specific primers for CTGF (5'-AAGACCTGTGGGATGGGC-3' and 5'-TGGTGCAAGCCAGAAAGCTC-3') were synthesized from IDT (San Diego, CA). To normalize the variation of the amount of mRNA in each reaction, 18S rRNA (primers: 5'-TTTGTTGGTTTTCGGAACTGA-3' and 5'-CGTTTATGGTCGGAACTACGA-3') was simultaneously processed in the same sample as an internal control. iQ SYBR Green Supermix from BIORAD (Hercules, CA) was used for real-time PCR reaction following the manufacturer’s procedure.

Standard curves for CTGF primers and 18S primers were constructed using serial 1 to 10 dilutions of the cDNA product from RT reaction (Fig. S6). The efficiency of CTGF primers was 99.46% and the efficiency of 18S primers was 97.43%. Dilutions of 1:1000, 1:100 and 1:10 were used in the assay and all of the samples were diluted by 1:100 for the real-time PCR reaction. To calculate relative changes in gene expression, we used the delta-delta method following the BIORAD’s introduction.

**Western Blot Analysis:** The same amounts of proteins from the cytosolic fraction, total cell lysates and retinal homogenates were resolved by SDS-PAGE (8% or 10%) and analyzed by Western blotting using specific antibodies. For cytosolic β-catenin measurement, cells were lysed by three frozen-thaw cycles in PBS with a protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN) followed by centrifugation, and the supernatants were isolated for Western blot analysis. For total cell lysates, harvested cells were sonicated in RIPA (Cell Signaling Technology, Danvers, MA) buffer containing 1% SDS. For retinal homogenate preparation, the retinas were homogenized in PBS with a protease inhibitor cocktail using a soft tissue pestle (Fisher Scientific Inc, Pittsburgh, PA). Antibodies for CTGF, LRP6 and β-catenin were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), and used at 1:400, 1:500 and 1:2500 dilutions. Antibody for β-actin (1:3000) was purchased from Invitrogen (Carlsbad, CA). Antibodies for phosphorylated LRP6 (S1490), phosphorylated β-catenin (S33/37/T41), phosphorylated GSK3β (S9), GSK3β and Histone H3 were purchased from Cell Signaling Technology (Danvers, MA), and used at 1:500 dilution for the first two antibodies and 1:2500 dilution for the last three antibodies. The monoclonal antibody for SERPINA3K (1:1000) was generated using the recombinant SERPINA3K through contracted service with Proteintech Group (Chicago, IL).

Because of the post-translational modifications, CTGF can display multiple bands with different molecular weights, which has been reported in the literature (33). Typically, a 36 or 38-KD band, or double bands at these molecular weights can be detected, dependent on the tissue, cell type and treatment. In the present study, CTGF showed double bands (36/38 KD) in the Western blotting data using the HTERT RPE-1 cell lysate.

**ELISA for Fibronectin:** Fibronectin concentrations in the retina homogenates were measured using an ELISA kit purchased from Assaypro (Winfield, MO) according to manufacturer’s instruction. The working range of the fibronectin ELISA kit used here is 4 ng/ml to 1000 ng/ml. All of the samples were measured in the linear part of the working range. The assay CVs are less than 2%. The total protein concentration was measured by Bradford protein assay.
Statistical Analysis: Student’s t test (two tailed) was used for comparisons between two groups. ANOVA was used for comparisons between groups in Table 1. Statistical significance was accepted when the P value was less than 0.05.

RESULTS
Clinical characteristics of diabetic animals: Two months after the induction of diabetes, the diabetic rats received an intravitreal (IVT) injection of adenovirus expressing SERPINA3K (Ad-SA3K, $5 \times 10^7$ pfu/eye), and the same titer of adenovirus expressing LacZ (Ad-LacZ) was injected for control. The rats were separated into four groups: normal rats without diabetes (control); rats with diabetes mellitus (DM); DM rats with injection of Ad-SA3K (DM-SA3K) and DM rats with injection of Ad-LacZ (DM-LacZ). There were 8 to 10 rats in each group. Before the STZ injection, all of these rats had similar blood glucose levels (~100 mg/dl) and similar body weights (~150 g). Three months after STZ injection, average body weight of the DM group (149±16g) was significantly lower than in non-diabetic control group (187±16g) (P<0.05). At each time point, there was no significant blood glucose or body weight difference between the DM group, DM-LacZ group and DM-SA3K group (Table 1), suggesting that the ocular adenovirus injection had no systemic effect in the diabetic animals.

A novel anti-fibrogenic activity of SERPINA3K in the retina with DR: To investigate the effect of SERPINA3K on fibrosis in the retina with DR, we measured the retinal levels of fibronectin in the STZ-induced diabetic rats. Fibronectin is an extracellular matrix protein, and overproduction of fibronectin has been shown to contribute to capillary basement membrane thickening in DR (34). Consistent with previous studies, our ELISA results showed that fibronectin levels were significantly higher in the retinas of the diabetic rats, compared to that in non-diabetic controls (Fig. 1). Ad-SA3K blocked retinal fibronectin over-expression in diabetic rats (Fig. 1), suggesting an anti-fibrogenic activity of SERPINA3K.

Retinal endothelial cells and pericytes are two major vascular cell types which are profoundly affected in DR, and their dysfunctions contribute to the blood retinal barrier (BRB) breakdown in DR (35-37). Since these cells are also the sources of fibronectin production responsible for thickening of the basement membrane, we measured the concentration of fibronectin in primary retinal pericytes and endothelial cells by ELISA. The high glucose-induced overproduction of fibronectin was attenuated by SERPINA3K in both of the cell types (Fig. S2).

Inhibitory effects of SERPINA3K on CTGF over-expression: The inhibitory effect of SERPINA3K on CTGF was evaluated in the STZ-induced diabetic rats. Four weeks after the injection of Ad-SA3K or Ad-LacZ, the retinas were dissected following a thorough perfusion to remove the blood in the retinal vasculature. As measured by Western blot analysis, retinal levels of SERPINA3K were decreased in the untreated diabetic rats, compared to that in non-diabetic rats (Fig. 2A, B). The Ad-SA3K injection resulted in an increase of SERPINA3K levels in the retinas of the diabetic rats (Fig. 2A, B). Retinal levels of CTGF were significantly increased in the retinas of untreated diabetic rats, compared to that in non-diabetic rats (Fig. 2A, B). The Ad-SA3K injection resulted in an increase of SERPINA3K levels in the retinas of the diabetic rats (Fig. 2A, B). Retinal levels of CTGF were significantly increased in the retinas of un-treated diabetic rats, compared with non-diabetic rats at the same age. The injection of Ad-SA3K mitigated the over-expression of CTGF in the retinas compared to the control Ad-LacZ virus (Fig. 2A, B).

It has been shown that retinal pigment epithelium (RPE) cells and retinal Müller cells are two major cell types expressing CTGF in the proliferative vitreoretinopathy (38). The diabetes-induced BRB breakdown
occurs predominantly at the level of the retinal blood vessels (39). However, the failure of the RPE barrier also occurs at a lower level, suggesting that the pathological change of the RPE is involved in diabetes (39). To evaluate the direct effect of SERPINA3K on the hyperglycemia-mediated CTGF over-expression in vitro, HTERT RPE-1 cells (human RPE cell line) and rMC-1 cells (rat retinal Müller cell line) were exposed to media containing 30 mM D-glucose (HG). CTGF expression was significantly elevated by high glucose exposure, when compared to low glucose control (5 mM D-glucose and 25 mM L-glucose, LG). SERPINA3K blocked the high glucose-induced CTGF over-expression in a dose-dependent manner in both of the cell lines (Fig. 2C, D).

To further study the mechanism for the regulation of CTGF by SERPINA3K, real-time RT-PCR was performed to measure mRNA levels of CTGF in the retinas and cultured retinal cells. The mRNA levels of CTGF were increased in the retinas with DR and decreased by Ad-SA3K (Fig. 3A). Similarly, exposure to high glucose media for 16 hr significantly elevated CTGF mRNA levels in both HTERT RPE-1 cells and rMC-1 cells. In a time course experiment, the cells were exposed to high glucose medium for 0-24 hr. The high glucose treatment continuously increased the CTGF mRNA level after 4 hr of exposure (Fig. S3). The high glucose-induced CTGF mRNA over-expression was attenuated by 100 nM SERPINA3K (Fig. 3B, C). Taken together, these results indicate that SERPINA3K blocks the hyperglycemia-induced CTGF expression at the transcription level.

The role of the high glucose-induced Wnt/β-catenin signaling in CTGF over-expression: To explore the signaling pathway mediating the inhibitory effect of SERPINA3K on CTGF transcription, we first investigated cell signaling responsible for CTGF over-expression induced by high glucose. As the β-catenin-TCF/LEF-binding (TBE) site was identified in the promoter region of the CTGF gene, and CTGF has been shown to be a target gene of β-catenin-TCF/LEF transcription factor (33), a downstream effector of the canonical Wnt pathway, we investigated the role of the Wnt pathway in the CTGF over-expression in diabetes. A number of Wnt ligands and Fz receptors and both LRP5 and 6 were found to express in the cultured HTERT RPE-1 cells by RT-PCR, suggesting that this cell line is a suitable model for Wnt signaling studies (Fig. S4). As phosphorylation of LRP6 is a critical step in the canonical Wnt pathway activation (40), we measured phosphorylated LRP6 (p-LRP6) levels. As shown by Western blot analysis using an antibody specific for p-LRP6, phosphorylation of the endogenous LRP6 was increased in the RPE cells exposed to 30 mM glucose, compared to that in control cells exposed to the low glucose medium (Fig. 4A). In the same cell line, cytosolic β-catenin levels were also elevated by the high glucose medium in an exposure time-dependent manner (Fig. 4A). Further, under high glucose conditions, phosphorylated β-catenin levels were decreased, compared to that in low glucose control (Fig. S5 A), while nuclear β-catenin levels were elevated (Fig. S5 B). Consistently, GSK3β phosphorylation (inactive form) was increased (Fig. S5 A). In vivo, cytosolic β-catenin levels in the retina homogenates were also significantly elevated in the diabetic rats, indicating an activation of the canonical Wnt pathway in the retinas with DR (Fig 4C, D). Further, when the Wnt pathway was blocked by Dickkopf1 (DKK1), a specific inhibitor of the canonical Wnt pathway, the high glucose-induced CTGF over-expression was attenuated (Fig. 4B), suggesting that the Wnt pathway activation induced by high glucose and diabetes is responsible for the CTGF over-expression.

Inhibitory effects of SERPINA3K on Wnt/β-catenin signaling in DR and high
glucose-treated retinal cells: To further investigate whether SERPINA3K inhibits the Wnt pathway in high glucose-treated cells and in diabetic retinas, SERPINA3K was delivered into the RPE cell culture medium containing high glucose and into the vitreous humor of diabetic rats. After 6 hr exposure, SERPINA3K decreased the high glucose-induced phosphorylation of LRP6 and accumulation of β-catenin in a concentration-dependent manner (Fig. 5A). SERPINA3K at 100 nM decreased p-LRP6 and cytosolic β-catenin to levels similar to that in the low glucose control (Fig. 5A). Similarly, 100 nM SERPINA3K completely reversed the high glucose-induced changes of phosphorylated β-catenin levels, nuclear β-catenin levels and phosphorylated GSK3β levels (Fig. S5 A, B). In diabetic rats, the injection of Ad-SA3K also blocked the accumulation of cytosolic β-catenin in the retina, compared to the control virus Ad-LacZ, suggesting an inhibitory effect of SERPINA3K on the canonical Wnt pathway in diabetes (Fig 5B, C).

The Wnt inhibitory effect of SERPINA3K was responsible for CTGF regulation: To determine whether SERPINA3K also blocks CTGF expression induced by Wnt signaling, the RPE cells were exposed to a 50% Wnt3a conditioned medium, with the 50% L cell medium as control. The Wnt3a conditioned medium elevated p-LRP6 and cytosolic β-catenin levels in the RPE cells (Fig. 6A, B). SERPINA3K at 100 nM blocked the increase of p-LRP6 and β-catenin levels induced by Wnt3a (Fig. 6A, B). TOPFLASH is a luciferase reporter construct under the control of a promoter containing the TCF/LEF-binding sites. To measure β-catenin-dependent reporter gene transcription, TOPFLASH activity assay was performed to further confirm the inhibitory effect of SERPINA3K on Wnt signaling. The RPE cells were transfected with the TOPFLASH construct and then incubated with the 50% Wnt3a conditioned medium. TOPFLASH assay showed that Wnt3a induced an approximate 3-fold increase in TOPFLASH reporter (TCF/LEF) activity, which was attenuated by SERPINA3K (Fig. 6C). These results indicated that SERPINA3K is a Wnt inhibitor.

To determine the effect of SERPINA3K on the Wnt-induced CTGF expression, the 50% Wnt3a conditioned medium was used to treat the cultured RPE cells. Wnt3a, as well as high glucose, induced CTGF over-expression in the RPE cells (Fig. 6D). Correlating with its inhibitory effect on Wnt signaling, SERPINA3K also inhibited the Wnt3a-induced CTGF up-regulation, similar to that in the high glucose model (Fig. 6D).

DISCUSSION

SERPINA3K is an extracellular serpin and has been found to function as an anti-angiogenic factor (5) and an anti-inflammatory factor (41). Our previous studies showed that SERPINA3K levels are decreased in the retina of diabetic rats (6). The present study revealed a novel anti-fibrogenic activity of this serpin, as it inhibits CTGF over-expression and reduces the production of extracellular matrix in the retina with DR. These findings suggest that decreased SERPINA3K levels in the diabetic retina may contribute to pathological fibrosis in DR. Further, our results demonstrate that the inhibitory effect of SERPINA3K on CTGF over-expression is through mitigating the Wnt signaling activation induced by diabetes.

Fibrosis is an important pathological feature of DR (7; 8). At early stages of DR, increased production of extracellular matrix has been shown to contribute to the capillary basement membrane thickening (42). At advanced stages of DR, fibrosis can result in contraction and retinal detachment, a major cause of blindness in DR (7; 8). The molecular mechanism for retinal fibrosis
A Novel Anti-fibrogenic Factor

DR is not clear. CTGF is a major fibrogenic factor, and its over-expression has been found to play a key role in the basement membrane thickening in DR models (14; 16). CTGF up-regulates production of extracellular matrix proteins such as fibronectin (43; 44). Therefore, CTGF is considered a promising target for treating retinal fibrosis in DR. The present study identified SERPINA3K as an endogenous inhibitor of CTGF and thus, an anti-fibrogenic factor in the retina. On the other hand, CTGF has been reported to bind to Wnt receptor/co-receptor (45). However, the function of CTGF in canonical Wnt signaling is still controversial (33; 45). Despite the possible feedback regulation by CTGF, blockade of Wnt signaling by SERPINA3K should result in a decrease of CTGF levels and inhibition of fibrogenesis, which supports our conclusion, i.e. the anti-fibrogenic effect of SERPINA3K is mediated, at least in part, through the Wnt pathway.

Our previous studies have shown that retinal levels of SERPINA3K are decreased in STZ-induced diabetic rats after 1, 2 and 4 months of diabetes (6). In the same animal model, CTGF over-expression was found in the diabetic rat retinas 3 months after STZ injection (13), correlating with the decrease of SERPINA3K. The disturbed balance between pro-fibrogenic factor CTGF and anti-fibrogenic factor SERPINA3K may represent a new pathogenic mechanism for the basement membrane thickening in DR.

Wnt signaling is involved in ocular diseases, such as vasculature disorders in the retina (23). Our recent study showed that activation of the Wnt pathway also plays a pathogenic role in subretinal neovascularization in an animal model of wet AMD (46). The role of Wnt signaling in pathological fibrosis has been revealed in some tissues, e.g. the lung (24). However, in most ocular diseases such as DR, the role of Wnt signaling, especially the association between Wnt signaling and retinal fibrosis remains obscure. Here, our results showed that cytosolic β-catenin, an essential effector of the canonical Wnt pathway, is accumulated in both diabetic retinas and in the high glucose-treated retinal cells. Phosphorylation of LRP6 is an early, yet essential step in activation of the canonical Wnt pathway, as the phosphorylation sites in the LRP6 intracellular domain are known to create inducible docking sites for Axin, leading to stabilization of β-catenin in the cytosol and transduction of the extracellular Wnt signal into intracellular compartments (40; 47). Our results showed that phosphorylated LRP6 levels were increased under high glucose conditions. In the hyperglycemia models, the induction of Wnt signaling activity was accompanied by CTGF over-expression. Same as the high glucose exposure, Wnt3a ligand also induced Wnt signaling activation and up-regulated CTGF expression, while DKK1, a specific inhibitor of the Wnt pathway, blocked the Wnt pathway activation. Therefore, our results revealed that Wnt signaling is activated in DR, which may be responsible for CTGF over-expression and retinal fibrosis.

Since DKK1 is a commonly accepted, specific inhibitor of the canonical Wnt pathway, DKK1 was used to specifically attenuate the Wnt signaling activation and further to reveal the role of Wnt signaling in the high glucose-induced CTGF over-expression. DKK1 has been reported to induce the internalization of LRP6 (48). To investigate the mechanism for the SERPINA3K effect on the Wnt pathway, we have measured several components of the Wnt pathway at different levels of the cascade. Further, we measured the cell surface level of LRP6 to determine the internalization of LRP6 using extracellular biotin labeling. Similar to DKK1, pre-incubation of the cells with SERPINA3K decreased the cell surface level of LRP6 (Fig. S5 C). This result suggests that induction of LRP6
internalization may represent a mechanism responsible, at least partially, for the inhibition of LRP6 phosphorylation by SERPINA3K.

There are 19 Wnt ligands, many of which function as agonists of Fz/LRP5/6 receptor complex and thus, activate Wnt/β-catenin signaling (49). On the other hand, some natural inhibitors of the Wnt pathway such as DKK family members and IGFBP-4 have been identified (50-52). Here we showed that SERPINA3K blocks the Wnt pathway activation induced by high glucose and by Wnt ligands, suggesting that SERPINA3K is a novel endogenous inhibitor of the Wnt pathway. SERPINA3K is known to specifically bind to tissue kallikrein, forming a covalent complex and inhibiting proteolytic activities of tissue kallikrein (3). Through interactions with the kallikrein-kinin system, SERPINA3K participates in the regulation of blood pressure and local blood flow (4). However, the kallikrein-binding activity cannot explain the broad functions of SERPINA3K, such as anti-angiogenic and anti-inflammatory activities (5; 41). In addition, some of these functions have proven to be independent of interactions with tissue kallikrein (5). The present study demonstrates that SERPINA3K has a potent Wnt antagonist activity. Since the Wnt pathway regulates multiple pathological processes, including angiogenesis, inflammation and fibrosis, the Wnt antagonizing activity of SERPINA3K may represent a unifying mechanism responsible for the broad beneficial effects of this serpin. As an endogenous inhibitor of the Wnt pathway, this serpin molecule may have therapeutic potential.

ACKNOWLEDGMENTS

This study was supported by NIH grants EY012231, EY018659, EY019390, and P20RR024215 from the National Center for Research Resources, and grants from OCAST and ADA.
REFERENCES
A Novel Anti-fibrogenic Factor


Table 1. Physiological parameters of diabetic rats

<table>
<thead>
<tr>
<th>Time after STZ injection</th>
<th>Blood glucose (mg/dl)</th>
<th>DM with Ad-IVT</th>
<th>DM with Ad-IVT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No Ad-IVT</td>
<td>P value</td>
<td>LacZ vs SA3K</td>
</tr>
<tr>
<td></td>
<td>Control vs DM</td>
<td></td>
<td>LacZ vs SA3K</td>
</tr>
<tr>
<td>-1 day</td>
<td>97±8</td>
<td>0.955</td>
<td>107±11</td>
</tr>
<tr>
<td>3 days</td>
<td>99±6</td>
<td>0.955</td>
<td>103±12</td>
</tr>
<tr>
<td>1 month</td>
<td>94±8</td>
<td>0.955</td>
<td>515±79</td>
</tr>
<tr>
<td>2 months</td>
<td>544±55</td>
<td>&lt;0.001</td>
<td>528±59</td>
</tr>
<tr>
<td>3 months</td>
<td>108±22</td>
<td>&lt;0.001</td>
<td>530±50</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time after STZ injection</th>
<th>Body weight (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No Ad-IVT</td>
</tr>
<tr>
<td></td>
<td>Control vs DM</td>
</tr>
<tr>
<td>-1 day</td>
<td>151±13</td>
</tr>
<tr>
<td>3 days</td>
<td>145±9</td>
</tr>
<tr>
<td>1 month</td>
<td>143±12</td>
</tr>
<tr>
<td>2 months</td>
<td>147±17</td>
</tr>
<tr>
<td>3 months</td>
<td>149±16</td>
</tr>
</tbody>
</table>

Data are means ± SD, n=8-10.

FIGURE LEGENDS

Figure 1. SERPINA3K attenuated over-expression of fibronectin in the retinas with DR. Ad-SA3K and Ad-LacZ were injected separately into the vitreous of diabetic rats, and the retinas were dissected 4 weeks following the injection. Retinal fibronectin levels were measured by ELISA and expressed as percentage of the retinal fibronectin level in the non-diabetic rats (mean±SD, n=6). *P<0.05.

Figure 2. SERPINA3K attenuated over-expression of CTGF in the retinas with DR and in retinal cells treated with high glucose. (A) STZ-induced diabetic rats (DM) received an intravitreal injection of Ad-SA3K, with Ad-LacZ as control. Four weeks after the injection, retinal levels of SERPINA3K and CTGF were measured by Western blot analysis using 100 µg of retinal proteins from each rat. (B) Retinal levels of SERPINA3K and CTGF were quantified by densitometry from 3 independent experiments and normalized by β-actin levels (*P<0.05, mean±SD, n=6). (C, D) rMC-1 cells (C) and HTERT RPE-1 cells (D) were exposed to low glucose (LG, 5 mM D-glucose + 25 mM L-glucose) and high glucose (HG, 30 mM D-glucose) media with various concentrations of SERPINA3K for 24 hr. Cellular CTGF levels were measured by Western blot analysis and normalized by β-actin levels.

Figure 3. SERPINA3K decreased CTGF mRNA levels in the diabetic retinas and in high glucose-treated cells. (A) Ad-SA3K and Ad-LacZ were injected intravitreally into the eyes of diabetic rats, and the retinas were dissected 4 weeks after the injection. (B, C) rMC-1 cells (B) and HTERT RPE-1 cells (C) were exposed to LG and HG media for 16 hr, with and without 100 nM SERPINA3K or BSA. Real-time RT-PCR was performed to quantify relative mRNA levels of CTGF in the retinas (A), rMC-1 cells (B) and RPE cells (C). Values are mean±SD, n=3. * P<0.05.
Figure 4. Wnt/β-catenin signaling was responsible for the high glucose-induced CTGF over-expression. (A) HTERT RPE-1 cells were exposed to HG for different durations as indicated. p-LRP6 levels were measured by Western blot analysis using 100 µg of total proteins with an antibody specific for p-LRPE6, and cytosolic β-catenin levels were determined by Western blot analysis using 20 µg cytosolic proteins. (B) HTERT RPE-1 cells were exposed to LG and HG media with 100 nM DKK1 or BSA. After 24 hr treatment of the cells, CTGF levels were measured by Western blot analysis. (C, D) The retinas were dissected from non-DM rats and DM rats. β-catenin levels in the retinal homogenates were measured by Western blot analysis (C) and quantified by densitometry (D; *P<0.05, mean±SD, n=6).

Figure 5. SERPINA3K inhibited the high glucose-induced Wnt/β-catenin signaling. (A) HTERT RPE-1 cells were exposed to LG and HG media for 6 hr with various concentrations of SERPINA3K. Levels of p-LRP6 and cytosolic β-catenin were determined by Western blot analysis. (B, C) The retinas were dissected from the diabetic rats 4 weeks after the intravitreal injection of Ad-LacZ or Ad-SA3K. β-catenin levels in the retinal homogenates were measured by Western blot analysis (B) and quantified by densitometry (C; mean±SD, n=6, *P<0.05).

Figure 6. SERPINA3K blocked the Wnt ligand-induced CTGF over-expression. (A, B) HTERT RPE-1 cells were exposed to 50% control L cell medium (LM) or 50% Wnt3a conditioned medium (WM) for 1 hr (A) or 2 hr (B), with 100 nM SERPINA3K or BSA. The same amounts of total cellular proteins (100 µg) (A) or cytosolic proteins (20 µg) (B) were blotted separately with antibodies specific for p-LRP6 and total LRP6 (A), or for β-catenin (B). (C) The cells were transfected with the TOPFLASH vector, followed by exposure to the LM or WM containing 1000 nM BSA or SERPINA3K for 24 hr. The TOPFLASH activity was measured using luciferase assay (mean±SD, n=3, *P<0.05). (D) HTERT RPE-1 cells were exposed to LM and WM media with 100 nM SERPINA3K or BSA. After culture for 24 hr, CTGF levels were measured by Western blot analysis.
A Novel Anti-fibrogenic Factor

FIGURE 2

A

<table>
<thead>
<tr>
<th></th>
<th>Non-DM</th>
<th>DM</th>
<th>Ad-LacZ</th>
<th>Ad-SA3K</th>
</tr>
</thead>
<tbody>
<tr>
<td>SA3K</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTGF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

Protein/β-actin (% of control)

Con | DM | Ad-LacZ | Ad-SA3K |

C

<table>
<thead>
<tr>
<th></th>
<th>Con</th>
<th>LG</th>
<th>HG + SA3K (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTGF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D

FIGURE 3

A

CTGF mRNA (% of Control)

Con | DM | Ad-LacZ | Ad-SA3K |

B

CTGF mRNA (% of Control)

Con | LG | BSA | SA3K |

C

CTGF mRNA (% of Control)

Con | LG | BSA | SA3K |

HG |
A Novel Anti-fibrogenic Factor

FIGURE 6

A

<table>
<thead>
<tr>
<th></th>
<th>WM</th>
</tr>
</thead>
<tbody>
<tr>
<td>LM</td>
<td></td>
</tr>
<tr>
<td>BSA</td>
<td></td>
</tr>
<tr>
<td>SA3K</td>
<td></td>
</tr>
</tbody>
</table>

p-LRP6
LRP6
β-actin

B

<table>
<thead>
<tr>
<th></th>
<th>WM</th>
</tr>
</thead>
<tbody>
<tr>
<td>LM</td>
<td></td>
</tr>
<tr>
<td>BSA</td>
<td></td>
</tr>
<tr>
<td>SA3K</td>
<td></td>
</tr>
</tbody>
</table>

β-catenin
β-actin

C

TCF/LEF activity (% of Control)

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LM</td>
</tr>
<tr>
<td>BSA</td>
</tr>
<tr>
<td>SA3K</td>
</tr>
</tbody>
</table>

D

<table>
<thead>
<tr>
<th></th>
<th>WM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Con</td>
<td></td>
</tr>
<tr>
<td>LM</td>
<td></td>
</tr>
<tr>
<td>BSA</td>
<td></td>
</tr>
<tr>
<td>SA3K</td>
<td></td>
</tr>
</tbody>
</table>

CTGF
β-actin